Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahmoud Aljurf

Showing results (121-130 of 403) with videos related to

Pageof 41
Sort By:
Frontiers in Immunology|March 6, 2026
Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignanciesKarama Makni-Maalej, Shaykhah Mujahhiz Alotaibi, Queenie Fernandes, et al.
Haematologica|June 4, 2026
Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemiaManar Aleid, Hissah Altuwayjiri, Muhned Alhumaid, et al.
Leukemia|May 27, 2021
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working PartyDonal P McLornan, Juan Carlos Hernandez-Boluda, Tomasz Czerw, et al.
Haematologica|March 20, 2013
Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational StudyAlois Gratwohl, Helen Baldomero, Michael Gratwohl, et al.
Haematologica|August 30, 2012
Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow TransplantationAlicia Rovó, Mahmoud Aljurf, Sandra Chiodi, et al.
Bone Marrow Transplantation|March 9, 2018
Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMTZinaida Peric, Stefano Botti, Jacqui Stringer, et al.
The Lancet. Haematology|December 22, 2015
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysisArnon Nagler, Bipin N Savani, Myriam Labopin, et al.
Transplantation and Cellular Therapy|October 20, 2021
Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic ThrombocytopeniaMaria Cancio, Kyle Hebert, Soyoung Kim, et al.
International Journal of Oncology|August 31, 2016
Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patientsAyodele A Alaiya, Mahmoud Aljurf, Zakia Shinwari, et al.
Hematology/Oncology and Stem Cell Therapy|July 22, 2017
Cost and quality issues in establishing hematopoietic cell transplant program in developing countriesShahrukh K Hashmi, Alok Srivastava, Walid Rasheed, et al.
Pageof 41

Showing results (121-130 of 403) with videos related to

Sort By:
Pageof 41
Frontiers in Immunology|March 6, 2026
Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignanciesKarama Makni-Maalej, Shaykhah Mujahhiz Alotaibi, Queenie Fernandes, et al.
Haematologica|June 4, 2026
Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemiaManar Aleid, Hissah Altuwayjiri, Muhned Alhumaid, et al.
Leukemia|May 27, 2021
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working PartyDonal P McLornan, Juan Carlos Hernandez-Boluda, Tomasz Czerw, et al.
Haematologica|March 20, 2013
Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational StudyAlois Gratwohl, Helen Baldomero, Michael Gratwohl, et al.
Haematologica|August 30, 2012
Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow TransplantationAlicia Rovó, Mahmoud Aljurf, Sandra Chiodi, et al.
Bone Marrow Transplantation|March 9, 2018
Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMTZinaida Peric, Stefano Botti, Jacqui Stringer, et al.
The Lancet. Haematology|December 22, 2015
Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysisArnon Nagler, Bipin N Savani, Myriam Labopin, et al.
Transplantation and Cellular Therapy|October 20, 2021
Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic ThrombocytopeniaMaria Cancio, Kyle Hebert, Soyoung Kim, et al.
International Journal of Oncology|August 31, 2016
Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patientsAyodele A Alaiya, Mahmoud Aljurf, Zakia Shinwari, et al.
Hematology/Oncology and Stem Cell Therapy|July 22, 2017
Cost and quality issues in establishing hematopoietic cell transplant program in developing countriesShahrukh K Hashmi, Alok Srivastava, Walid Rasheed, et al.
Pageof 41